Cresco Labs is trading 5.8% down at $0.77 after August 24, 2026 coverage highlighted sweeping consumer class-action and RICO allegations involving the company.
- The allegations remain unproven but add legal and potential insurance-cost uncertainty.
- Bloomberg Law previously reported that Palomar sued Cresco, seeking a declaration that it has no duty to defend the underlying lawsuits, intensifying investor concerns.
- Broader markets are mixed, while consumer staples are higher on defensive rotation; neither clearly explains the cannabis-stock-specific decline.